
Am J Psychiatry 156:1279-1281, August 1999
© 1999 American Psychiatric Association
Tetrabenazine Treatment for Tardive Dyskinesia: Assessment by Randomized Videotape Protocol
William G. Ondo, M.D.,
Philip A. Hanna, M.D., and
Joseph Jankovic, M.D.
OBJECTIVE: Tetrabenazine, a monoamine depleter and dopamine receptor blocker, is used to treat several hyperkinetic movement disorders. The authors studied the use of tetrabenazine for tardive dyskinesia. METHOD: Twenty patients with tardive dyskinesia (mean duration=43.7 months) were videotaped before and after tetrabenazine treatment. Randomized videotapes were scored with the motor subset of the modified Abnormal Involuntary Movement Scale (AIMS) by raters blind to pre- or posttreatment status. RESULTS: One patient did not tolerate tetrabenazine owing to sedation. The remaining 19 were rated after a mean of 20.3 weeks at a mean tetrabenazine dose of 57.9 mg/day. There were significant improvements in mean scores on both the patient AIMS self-rating and the AIMS motor subset evaluated by the blind videotape raters. All 19 patients continued to take tetrabenazine after the study. CONCLUSIONS: Tetrabenazine was well tolerated and resulted in significant improvements in AIMS scores for patients with refractory tardive dyskinesia.
This article has been cited by other articles:

|
 |

|
 |
 
Huntington Study Group
Tetrabenazine as antichorea therapy in Huntington disease: A randomized controlled trial
Neurology,
February 14, 2006;
66(3):
366 - 372.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Get information about faster international access.
a>
Privacy Policy
Copyright © 1999
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|